Benzonaphthyridinamines as autotaxin inhibitors

US9029387B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Wolfgang Staehle · Ingelheim am Rhein, DE
• Melanie Schultz · Darmstadt, DE
• Kai Schiemann · Darmstadt, DE

Key dates

• Filing date: Feb 28, 2011
• Grant date: May 12, 2015
• Expiry date: Sep 7, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to benzonaphthyridinamines of the formula (I) as autotaxin inhibitors and to the use thereof in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in which the inhibition, regulation and/or modulation of phosphodiesterase or lysophospholipase autotaxin plays a role, in particular of various types of cancer and autoimmune and inflammatory diseases.